Full Press Release Details
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib a cMET Inhibitor.
IDYA
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib a cMET Inhibitor
Key Takeaway: IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib a cMET Inhibitor